Jul 29, 2019 17:49 JST

Source: NEC Corporation

NEC Acquires Norwegian Bioinformatics Company, OncoImmunity AS

TOKYO, Jul 29, 2019 - (JCN Newswire) - NEC Corporation (TSE: 6701) has announced the acquisition of OncoImmunity AS, a Norway-based bioinformatics company that develops proprietary machine learning software to support the fight against cancer. OncoImmunity AS will now become a subsidiary of NEC and operate under the name of NEC OncoImmunity AS.

OncoImmunity AS, founded in 2014, is a bioinformatics company dedicated to the development of software solutions that facilitate the effective selection of patients for cancer immunotherapy, and identify optimal neoantigen targets for truly personalized cancer vaccines and cell therapies in a clinically actionable time frame.

NEC announced its business strategy surrounding its AI-driven drug discovery business in May 2019. This acquisition is integral for enhancing the resources and capabilities that support the development of its individualized immunotherapy pipelines. NEC will maintain its focus on drug discovery, while NEC OncoImmunity AS continues its neoantigen prediction services.

Sharing a common vision, both NEC and OncoImmunity AS firmly believe in improving individualized cancer treatments through Artificial Intelligence (AI). AI holds great promise in enabling each and every patient to receive the most appropriate medication.

"The OncoImmunity AS team are delighted to be joining the NEC Group and firmly believe that the union will realize great synergies, marrying the mutual strengths of OncoImmunity AS's and NEC's neoantigen prediction pipelines with NEC's expertise in AI, data management and security. These synergies will help strengthen NEC's individualized immunotherapy programs, whilst simultaneously positioning NEC OncoImmunity AS as the leading neoantigen prediction service provider in the field," said Dr. Richard Stratford, Chief Executive Officer and Co-founder of OncoImmunity AS.

"NEC strongly believes that healthcare based on genomics paves the way for individualized medicine. OncoImmunity AS is a recognized player in the neoantigen prediction field, and their compelling systems are expected to form valuable synergies with NEC. We are confident that this acceleration of development will provide promising new avenues that lead to better cancer treatments," said Osamu Fujikawa, Senior Vice President, NEC Corporation.

Contact:
NEC 
Seiichiro Toda         
s-toda@cj.jp.nec.com 
+81-3-3798-6511
Source: NEC Corporation
Sectors: CyberSecurity

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Executive Appointments in Connection with the Establishment of NESIC Holdings
June 23 2025 18:22 JST
 
NEC and Chugai Pharmaceutical use AI to potentially enhance cancer treatment
June 18 2025 12:40 JST
 
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 months with Individualized Cancer Vaccine TG4050
June 02 2025 16:56 JST
 
IFS and NEC Strengthen their Strategic Partnership to Create New Value
May 30 2025 09:11 JST
 
NEC DGDF Headquarters relocates to Zurich to accelerate growth and enhance management globally
April 28 2025 15:03 JST
 
NEC invests in U.S.-based "Geodesic Alliance Fund" aiming to strengthen economic security business
April 24 2025 09:23 JST
 
NEC Face Recognition Ranks First in NIST Accuracy Testing
April 09 2025 10:09 JST
 
NEC Orchestrating Future Fund invests in Rescale, Inc., provider of a leading digital engineering platform for cloud high-performance computing (HPC)
April 08 2025 15:42 JST
 
SITA and NEC Collaborate to Drive Global Adoption of Digital Identities in Travel
April 08 2025 15:11 JST
 
NEC has developed technologies that enable a secure workflow for personalized cancer vaccines and has proven their capabilities
April 01 2025 15:15 JST
 
More Press release >>

Latest Press Release


More Latest Release >>